Glaukos Medical (GKOS) - מקדם חוב לטווח ארוך להון

Glaukos Corporation (GKOS) is expanding its competitive advantage through the implementation of innovative slow-release implants and the protection of intellectual property. However, profit potential is constrained by medical insurance complexities and potential failures in new development trials. The current metric stands at 0.15. This daily price chart complements the analysis of this glaucoma microsurgery pioneer, which is creating safe alternatives to eye drops.

Glaukos Corporation (GKOS) leadership in minimally invasive surgery and its patent-protected implants create a powerful foundation for organic growth without excessive borrowing. The current value of 0.15 on the long-term debt-to-equity chart reflects the proportion of liabilities with a maturity of over one year relative to equity, where a downward trend confirms financial stability but may signal an underutilization of leverage for expansion.